DRUG (Bright Minds Biosciences) Total Assets: $227.67 Mil (As of Mar. 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Total Assets?

Bright Minds Biosciences DRUG +3.35% 34 Total Assets is $227.67 Mil as of Mar. 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Bright Minds Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $227.67 Mil.

During the past 12 months, Bright Minds Biosciences's average Total Assets Growth Rate was 293.00% per year. During the past 3 years, the average Total Assets Growth Rate was 48.80% per year. During the past 5 years, the average Total Assets Growth Rate was 50.90% per year.

During the past 6 years, Bright Minds Biosciences's highest 3-Year average Total Assets Growth Rate was 48.80%. The lowest was 11.20%. And the median was 17.90%.

Total Assets is connected with ROA %. Bright Minds Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -20.78%. Total Assets is also linked to Revenue through Asset Turnover. Bright Minds Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Bright Minds Biosciences  (NAS:DRUG) Total Assets Explanation

Total Assets is connected with ROA %.

Bright Minds Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-30.496/( (65.879+227.671)/ 2 )
=-30.496/146.775
=-20.78 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Bright Minds Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (65.879+227.671)/ 2 )
=0/146.775
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Bright Minds Biosciences Total Assets Related Terms

Bright Minds Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences Total Assets Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Assets
Get a 7-Day Free Trial 15.82 9.06 5.08 4.51 61.03

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.34 38.41 61.03 65.88 227.67
DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Bright Minds Biosciences's Total Assets for the fiscal year that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (A: Sep. 2025 )+Total Liabilities (A: Sep. 2025 )
=59.307+1.718
=61.03

Bright Minds Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=224.878+2.794
=227.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $227.67 Mil mean?
Bright Minds Biosciences (DRUG) has a Total Assets of $227.67 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Total Assets too high?
Bright Minds Biosciences' current Total Assets is $227.67 Mil. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Total Assets compare to VRTX and REGN?
Bright Minds Biosciences' Total Assets of $227.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Total Assets is $227.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Total Assets of $227.67 Mil. The current Total Assets is $227.67 Mil. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Total Assets is $227.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price